

Pancreatic adenocarcinomas with mature blood vessels have better overall survival

Eriko Katsuta¹, Qianya Qi², Xuan Peng², Steven N. Hochwald^{1,3}, Li Yan², Kazuaki Takabe^{1,3-7}

¹ Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA

² Department of Biostatistics and Bioinformatics, Roswell Park Cancer Institute, Buffalo, NY, USA

³ Department of Surgery, University at Buffalo the State University of New York, Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY, USA

⁴ Department of Breast Surgery and Oncology, Tokyo Medical University, Tokyo, Japan

⁵ Department of Surgery, Yokohama City University, Yokohama, Japan

⁶ Department of Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan

⁷ Department of Breast Surgery, Fukushima Medical University, Fukushima, Japan

Corresponding author

Kazuaki Takabe, MD, PhD, FACS

Department of Surgical Oncology

Roswell Park Cancer Institute

Elm & Carlton Streets, Buffalo NY 14263 USA

Tel: 716-845-5540, FAX: 716-845-5705

Email: kazuaki.takabe@roswellpark.org

Supplementary Table 1: Significantly differentially expressed KEGG pathways between CD31 high and low tumors

ID	Description	GeneRatio	BgRatio	pvalue	p.adjust
hsa04514	Cell adhesion molecules (CAMs)	64/874	145/7277	1.21E-22	3.66E-20
hsa04640	Hematopoietic cell lineage	41/874	97/7277	3.98E-14	4.66E-12
hsa05150	Staphylococcus aureus infection	30/874	56/7277	4.64E-14	4.66E-12
hsa04062	Chemokine signaling pathway	55/874	185/7277	5.07E-11	3.82E-09
hsa05144	Malaria	24/874	49/7277	1.97E-10	1.18E-08
hsa04380	Osteoclast differentiation	42/874	128/7277	3.56E-10	1.79E-08
hsa04060	Cytokine-cytokine receptor interaction	66/874	270/7277	5.99E-09	2.58E-07
hsa05140	Leishmaniasis	28/874	74/7277	9.32E-09	3.50E-07
hsa05323	Rheumatoid arthritis	29/874	90/7277	3.04E-07	1.02E-05
hsa04659	Th17 cell differentiation	32/874	107/7277	5.09E-07	1.53E-05
hsa05145	Toxoplasmosis	33/874	113/7277	6.21E-07	1.65E-05
hsa04660	T cell receptor signaling pathway	31/874	103/7277	6.57E-07	1.65E-05
hsa05152	Tuberculosis	45/874	179/7277	7.25E-07	1.68E-05
hsa04015	Rap1 signaling pathway	49/874	210/7277	2.47E-06	5.31E-05
hsa04611	Platelet activation	33/874	123/7277	4.94E-06	9.92E-05
hsa05142	Chagas disease (American trypanosomiasis)	29/874	102/7277	5.36E-06	0.000101
hsa04658	Th1 and Th2 cell differentiation	27/874	92/7277	5.86E-06	0.000104
hsa04672	Intestinal immune network for IgA production	18/874	49/7277	6.91E-06	0.000115
hsa05416	Viral myocarditis	20/874	59/7277	8.88E-06	0.000141
hsa04610	Complement and coagulation cascades	24/874	79/7277	1.00E-05	0.000151
hsa04670	Leukocyte transendothelial migration	30/874	112/7277	1.37E-05	0.000196
hsa04064	NF-kappa B signaling pathway	26/874	95/7277	3.39E-05	0.000464
hsa05330	Allograft rejection	14/874	38/7277	7.01E-05	0.000918
hsa04145	Phagosome	35/874	152/7277	8.98E-05	0.001127
hsa04014	Ras signaling pathway	47/874	227/7277	0.000104	0.001255
hsa05310	Asthma	12/874	31/7277	0.000133	0.001541
hsa05200	Pathways in cancer	72/874	395/7277	0.000142	0.001588
hsa05321	Inflammatory bowel disease (IBD)	19/874	65/7277	0.000148	0.00159
hsa05332	Graft-versus-host disease	14/874	41/7277	0.000181	0.001854
hsa05221	Acute myeloid leukemia	19/874	66/7277	0.000185	0.001854
hsa04940	Type I diabetes mellitus	14/874	43/7277	0.000319	0.003051
hsa05320	Autoimmune thyroid disease	16/874	53/7277	0.000324	0.003051
hsa05133	Pertussis	20/874	76/7277	0.000471	0.004296
hsa05166	HTLV-I infection	49/874	255/7277	0.000487	0.004314
hsa05322	Systemic lupus erythematosus	29/874	133/7277	0.000909	0.00782
hsa05162	Measles	29/874	134/7277	0.001031	0.008621
hsa04933	AGE-RAGE signaling pathway in diabetic complications	23/874	99/7277	0.001227	0.00998
hsa04924	Renin secretion	17/874	65/7277	0.001322	0.010473
hsa04666	Fc gamma R-mediated phagocytosis	21/874	91/7277	0.002148	0.01658
hsa05340	Primary immunodeficiency	11/874	37/7277	0.003134	0.023014
hsa04022	cGMP-PKG signaling pathway	32/874	163/7277	0.003135	0.023014
hsa04662	B cell receptor signaling pathway	17/874	71/7277	0.003665	0.026265
hsa04724	Glutamatergic synapse	24/874	114/7277	0.003947	0.027632
hsa04921	Oxytocin signaling pathway	30/874	153/7277	0.004233	0.028027
hsa05202	Transcriptional misregulation in cancer	35/874	186/7277	0.00426	0.028027
hsa04270	Vascular smooth muscle contraction	25/874	121/7277	0.004283	0.028027
hsa04630	Jak-STAT signaling pathway	30/874	156/7277	0.005668	0.036298
hsa04510	Focal adhesion	36/874	199/7277	0.007259	0.045517
hsa04512	ECM-receptor interaction	18/874	82/7277	0.00751	0.046135
hsa04650	Natural killer cell mediated cytotoxicity	26/874	133/7277	0.007741	0.046601
hsa04340	Hedgehog signaling pathway	12/874	47/7277	0.008025	0.047366

